Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation
| Autor: | Jing Zeng, Stephen R. Bowen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Lung Neoplasms Quantitative imaging Durvalumab Treatment intensification Locally advanced Article 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Dose escalation medicine Humans Radiology Nuclear Medicine and imaging business.industry Combined modality treatment Chemoradiotherapy Concurrent chemoradiation Combined Modality Therapy 030220 oncology & carcinogenesis Unselected population business |
| Zdroj: | Semin Radiat Oncol |
| ISSN: | 1053-4296 |
| DOI: | 10.1016/j.semradonc.2020.11.007 |
| Popis: | The best survival for patients with unresectable, locally advanced NSCLC is currently achieved through concurrent chemoradiation followed by durvalumab for a year. Despite the best standard of care treatment, the majority of patients still develop disease recurrence, which could be distant and/or local. Trials continue to try and improve outcomes for patients with unresectable NSCLC, typically through treatment intensification, with the addition of more systemic agents, or more radiation dose to the tumor. Although RTOG 0617 showed that uniform dose escalation across an unselected population of patients undergoing chemoradiation is not beneficial, efforts continue to select patients and tumor subsets that are likely to benefit from dose escalation. This review describes some of the ongoing therapeutic trials in unresectable NSCLC, with an emphasis on quantitative imaging and precision radiation dose escalation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect